Literature DB >> 11699892

Lentiviral vectors for the treatment of neurodegenerative diseases.

E Martin-Rendon1, M Azzouz, N D Mazarakis.   

Abstract

A number of potential gene therapy applications in the adult nervous system include neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. During the last five years, lentiviral vectors have developed into extremely efficient gene transfer vehicles to the nervous system, revealing a wide range of possibilities for the treatment or such disorders. This review describes the most important and recent advances in the development of lentiviral vectors as well as the demonstration of proof-of-principle in animal models of human neurodegenerative diseases.

Entities:  

Mesh:

Year:  2001        PMID: 11699892

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  4 in total

1.  Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy.

Authors:  Mimoun Azzouz; Thanh Le; G Scott Ralph; Lucy Walmsley; Umrao R Monani; Debbie C P Lee; Fraser Wilkes; Kyriacos A Mitrophanous; Susan M Kingsman; Arthur H M Burghes; Nicholas D Mazarakis
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 2.  Therapeutic gene silencing in neurological disorders, using interfering RNA.

Authors:  G Scott Ralph; Nicholas D Mazarakis; Mimoun Azzouz
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

Review 3.  The cell biology of rabies virus: using stealth to reach the brain.

Authors:  Matthias J Schnell; James P McGettigan; Christoph Wirblich; Amy Papaneri
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

4.  Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells.

Authors:  Marie Soukupová; Silvia Zucchini; Pascal Trempat; Selene Ingusci; Coline Perrier-Biollay; Mario Barbieri; Stefano Cattaneo; Barbara Bettegazzi; Simonetta Falzoni; Hervé Berthommé; Michele Simonato
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-29       Impact factor: 6.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.